Alder Bio Pharmaceuticals, Inc.
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:acquisition |
acquired by Lundbeck
|
| gptkbp:focus |
monoclonal antibodies
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:founder |
gptkb:Randall_C._Schatzman
|
| gptkbp:headquarters |
gptkb:Bothell,_Washington
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alder Bio Pharmaceuticals, Inc.
|
| gptkbp:products |
gptkb:Eptinezumab
|
| gptkbp:symbol |
ALDR
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:Company
|